New imaging for diagnosing lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new imaging method called CXCR4 PET/CT that may help doctors better see and understand lymphomas (a type of blood cancer). It is for people who are newly diagnosed or suspected of having lymphoma and have already had a standard PET/CT.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are suspected or confirmed to have a lymphoma (a type of blood cancer) and have not yet started treatment.
- You have had a PET/CT scan with FDG tracer in the last 2 weeks.
- You are not pregnant or breastfeeding.
- You are not allergic to Pentixafor (the experimental tracer in this study).
- You must be willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
This trial compares a new type of PET/MR scan (using a radioactive tracer called Ga-68 PentixaFor) with standard imaging to see if it can better detect multiple myeloma at diagnosis and during follow-up. It may help improve staging and treatment planning.
This study uses a special PET/CT scan to learn more about lymphoma in adults. The scan may help doctors better understand your cancer and guide treatment decisions.
This trial looks at whether PET/CT scans can better predict outcomes in people with fast-growing lymphoma. If you are newly diagnosed and receiving standard treatment, the study may help refine how response is evaluated.
This trial tests a new PET/CT imaging tracer called [18F]BL40 to see if it can help spot certain types of blood cancers. It may help doctors better understand and monitor these diseases.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.